Global Biomarkers Markets, Technology & Competitive Landscape Report 2020-2021 & 2030: Focus on Proteomics, Metabolomics, Molecular Diagnostics, Drug Discovery, Clinical Trials, and Bioinformatics - ResearchAndMarkets.com

·3 min read

DUBLIN, November 29, 2021--(BUSINESS WIRE)--The "Biomarkers - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

This report describes different types of biomarkers and their discovery using various "-omics" technologies such as proteomics and metabolomics. Molecular diagnostics technologies are used for the discovery of biomarkers and new tests are also based on biomarkers.

This report follows the broad definition of a biomarker as a characteristic that can be objectively measured and evaluated as an indicator of normal biological or pathogenic processes as well as pharmacological responses to a therapeutic intervention. Tests based on biomarkers have been around for more than half a century, but interest in their application for diagnostics and drug discovery as well as the development has increased remarkably since the beginning of the 21st century.

Currently, the most important applications of biomarkers are in drug discovery and development. The role of biomarkers in various therapeutic areas particularly cancer, cardiovascular diseases and disorders of the central nervous system, is described. Biomarkers are useful not only for the diagnosis of some of these diseases but also for understanding the pathomechanism as well as a basis for the development of therapeutics.

Biomarkers will facilitate the combination of therapeutics with diagnostics and will thus play an important role in the development of personalized medicine. Biomarkers play a role in the use of pharmacogenetics, pharmacogenomics, and pharmacoproteomics for the development of personalized medicine.

Many of the regulatory issues concerning biomarkers are related to genomics, proteomics, molecular diagnostics, and pharmacogenomics/pharmacogenetics. Validation of biomarkers and their role in clinical trials are discussed.

Biomarker markets are estimated from 2020 to 2030 according to share of markets for various technologies and applications: proteomics, metabolomics, molecular diagnostics, drug discovery, clinical trials, and bioinformatics. Market values are further split according to therapeutic applications and major geographical areas. Unfulfilled needs in biomarkers are identified as well as the drivers for biomarker markets. Challenges facing the biomarker industry and strategies for developing biomarker markets are discussed.

A large number of companies with varying technical backgrounds are involved in biomarkers and 300+ of these are profiled in part 2 of the report with classification into various categories. These also include major pharmaceutical companies.

Markets for Biomarkers

  • Biomarker markets according to technologies/applications

  • Markets for protein biomarkers

  • Biomarker market relevant to drug discovery and development

  • Proteomic biomarker-based drug discovery

  • Biomarker market relevant to epigenetics

  • Biomarker market relevant to bioinformatics

  • Biomarker markets according to therapeutic areas

  • Markets for cancer biomarkers

  • Geographical distribution of biomarker markets

  • Drivers for the growth of markets for biomarkers

  • Biomarker patents

  • Factors that enhance the value of biomarker IP

  • US policy on patenting relevant to biomarkers

  • US legal decisions on gene patenting

  • Strategies for developing biomarker markets

  • Utilization of biomarker research in academic laboratories.

  • Biomarker discovery at pharmaceutical companies

  • Industrial-academic collaborations in biomarkers

  • Unfulfilled needs in biomarkers

  • Challenges facing the biomarker industry

  • Application of biomarkers in healthcare

  • Applications of biomarkers beyond healthcare

  • Combating bioterrorism

  • Biomarkers for monitoring human exposure to environmental toxins

Key Topics Covered:

Part 1: Technologies & Applications

Executive Summary

1. Introduction

2. Technologies for Discovery of Biomarkers

3. Biomarkers and Molecular Diagnostics

4. Biomarkers for Drug Discovery & Development

5. Role of Biomarkers in Healthcare

6. Biomarkers in Metabolic Disorders

7. Biomarkers in Immune Disorders

8. Biomarkers of Musculoskeletal Disorders

9. Biomarkers of Infectious Diseases

10. Biomarkers of Genetic Disorders

11. Biomarkers of Aging

12. Nutritional Biomarkers

13. Biomarkers of Cancer

14. Biomarkers of Disorders of the Nervous System

15. Biomarkers of Cardiovascular Disorders

16. Biomarkers of Pulmonary Diseases

17. Biomarkers in Gynecology and Obstetrics

18. Biomarkers & Personalized Medicine

19. Biomarkers and Regulatory issues

20. References

Part II: Markets & Companies

21. Markets for Biomarkers

22. Companies

For more information about this report visit https://www.researchandmarkets.com/r/gn045p

View source version on businesswire.com: https://www.businesswire.com/news/home/20211129005530/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting